Middle East study of bloodstream infections in blood cancer patients and HSCT recipients
Official title: Middle East Study of Infections in Patients With Hematological Malignancies
Run by Hamad Medical Corporation · NCT07900542 · Data updated 2026-11-12
This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 9 sites (Amman and 8 other locations) |
| Status | Recruiting |
| Started | September 15, 2024 |
| Main results expected | November 30, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | October 30, 2026 |
| Trial ID | NCT07900542 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with an active hematological malignancy or a history of HSCT who develop a bloodstream infection.
✕Probably not a fit
Patients whose infections are unrelated to hematologic disease or those not experiencing BSI may not derive direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will prospectively track bloodstream infection episodes in adults with hematological malignancies or HSCT recipients at multiple centers in Qatar, Saudi Arabia, Oman, UAE, and Jordan. The study will collect data on patient characteristics, infection details, treatments, and outcomes up to 30 days after the index blood culture. The goal is to describe epidemiology, identify risk factors for inappropriate therapy and for persistent infection, microbiological relapse, and mortality. No experimental interventions are planned; care remains at the treating clinician's discretion.
Why it matters
Potential benefit: If successful, the study could improve understanding of BSI patterns and help guide more effective management in this population.
How similar studies have gone: Other regions have shown that BSI epidemiology and treatment guidance can improve outcomes; this study extends those efforts to the Middle East.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active underlying hematological malignancy or hematopoietic stem cell transplant recipient. * Bloodstream infection ( a blood culture yielding a growth of ≥1 micro-organism that is considered to be clinically significant and is actively treated by the attending physicians). Exclusion Criteria: * A bloodstream infection within 14 days of an already enrolled bloodstream infection, or at any time before resolution of active signs of infections associated with an already enrolled episode.
Where it's running
-
King Hussein Cancer Center
Amman, Jordan Recruiting -
Royal Hospital
Muscat, Oman Recruiting -
Hamad Medical Corporation
Doha, Qatar Recruiting -
King Fahad Specialist Hospital
Dammam, Saudi Arabia Recruiting -
King Abdullah International Medical Research Center
Jeddah, Saudi Arabia Recruiting -
King Faisal Specialist Hospital and Research Center, Jeddah
Jeddah, Saudi Arabia Recruiting
Show 3 more locations
-
King Faisal Specialist Hospital and Research Center, Riyadh
Riyadh, Saudi Arabia Recruiting -
Sheikh Shakbout Medical City
Abu Dhabi, United Arab Emirates Recruiting -
Rashid Hospital
Dubai, United Arab Emirates Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral switch for bloodstream infections in immunocompromised children
This trial tests whether switching from IV to oral antibiotics is just as safe as continuing IV therapy for children with bloodstream infections who are immunocompromised or have a central venous catheter.
-
Oral switch for kids with bloodstream infections after starting IV therapy
This trial will test whether switching from IV to oral antibiotics early is not worse than continuing IV treatment for previously healthy children and teens with uncomplicated bloodstream infections.
-
Withaferin A to help prevent graft-versus-host disease after stem cell transplant
This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.
-
Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant
This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.
-
Sulbactam-Durlobactam for CRAB infections in real-world care
This real-world study tests whether sulbactam-durlobactam works and is safe for adults with carbapenem-resistant Acinetobacter baumannii infections, compared with other anti-CRAB treatments.
-
Fast antibiotic sensitivity tests to guide treatment for bloodstream infections
This tests whether rapid antibiotic susceptibility tests can help doctors pick the right antibiotics sooner for adults with positive blood cultures and improve recovery and antibiotic use.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.